Position in ZYME
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$12,717,868
-$12,502,670 QoQ
Shares Held
486,529
-51.7% QoQ
Ownership
0.686%
of shares outstanding
% of Portfolio
1.02%
of 13F equity value
Holder Rank
#21
of 202 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Capricorn Fund Managers Ltd holds $71,636,795 across 13 Biotechnology names. ZYME ranks #2 (17.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
321,721 | $18,276,970 | |
| 2 | ZYME |
Zymeworks Inc.
This page
|
486,529 | $12,717,868 | |
| 3 | MIRM |
Mirum Pharmaceuticals, Inc.
|
101,240 | $11,852,166 | |
| 4 | MLTX |
MoonLake Immunotherapeutics
|
374,866 | $7,298,641 | |
| 5 | CYTK |
Cytokinetics Inc
|
81,879 | $6,975,272 | |
| 6 | PTCT |
Ptc Therapeutics, Inc.
|
63,900 | $5,212,323 | |
| 7 | PVLA |
Palvella Therapeutics, Inc.
|
14,088 | $2,152,928 | |
| 8 | COGT |
Cogent Biosciences, Inc.
|
41,300 | $1,598,310 |
All Filings in ZYME
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $12,717,868 | 486,529 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | $25,220,538 | 1,007,210 | Shares | Sole | 2026-04-24 | |
| 2025-12-31 | $26,931,377 | 1,022,840 | Shares | Sole | 2026-01-21 | |
| No filing history on record for this holder in this stock. | ||||||